Pancreatic cancer with liver metastasis benefits from chemoradiotherapy compared to chemotherapy alone: a retrospective cohort study from the Surveillance, Epidemiology, and End Results (SEER) database.

ABSTRACT:

Background

Pancreatic cancer with metastasis carries a poor prognosis. Whether chemoradiotherapy (CRT) offers additional benefit over chemotherapy (CT) alone for metastatic pancreatic cancer remains unclear. This study aimed to evaluate the efficacy of CRT compared with CT alone in patients with metastatic pancreatic cancer and to investigate the consistency of the effect across different metastatic sites using the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

Patients diagnosed with metastatic pancreatic cancer from 2010 to 2015 were identified from the SEER database. Inclusion criteria were age ≥18 years, pathologically confirmed pancreatic cancer, survival time of at least 3 months, documented CT and radiotherapy (RT) status, and complete clinical a

SUBMITTER: He L 

PROVIDER: S-EPMC12554462 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature